REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.-MedSci.cn

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.

Seckl, M; Ghorani, E; Quartagno, M; Blackhall, FH; Gilbert, DC; O'Brien, MER; Ottensmeier, CHH; Pizzo, E; Spicer, JF; Williams, A; Badman, PD; Parmar, MKB

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16):

科室
- - 订阅+
  - 更多科室
工具
服务